|
"We live in times of great challenges and opportunities for developing new drugs for CNS disorders. While traditional clinical outcomes remain necessary, the information captured by these outcomes is often noisy, dated, and superficial. Methods such as biomarkers, imaging, and cognitive performance testing are promising endpoints for CNS trials however implementation, interpretation, and validation are major issues. Moreover, the development of standards for these technologies is a task that must be shared by sponsors, vendors, and investigators. The conference on Clinical Trials in CNS organized by SMi is an excellent opportunity to learn from each other as we confront these tasks." Mark Schmidt, Director and Clinical Expert, CNS, Johnson & Johnson
With recent media attention focussed on the clinical trials of anti-depressants, CNS drugs and their trials have come under fire. Following last year's success, SMi are proud to present their 7th Annual Clinical Trials in CNS conference which will bring you the latest on clinical trial optimisation, pitfalls and considerations. Don't miss this opportunity to hear the latest developments in CNS clinical trials from reknowned industry experts including:
 | Stephen Wright, Director, Research and Development, GW Pharmaceuticals |
 | Malcolm Barratt-Johnson, Managing Partner, The BJ Partnership LLP &Consulting Medical Assessor, MHRA |
- Mark Schmidt, Director and Clinical Expert, CNS, Johnson & Johnson
- J Findlay Walker, Vice President, EU Administration, Daiichi Sankyo
- Fiona Guillard, Drug Development Sciences, GlaxoSmithKline
- Boris Chizh, Director, Exploratory Pain Medicine, GlaxoSmithKline
- Corinne Hagger, Clinical Research Scientist, Merck Serono
- Keith Wesnes, Chief Executive, Cognitive Drug Research
- Sophie Dix, Group Leader, Eli Lilly
- Alan Lenox-Smith, Senior Medical Advisor, Wyeth
- Malek Bajbouj,Director and Principal Consultant CNS Services Clinical Pharmacology,Parexel
Who should attend: Medical Directors Director of Metabolic Diseases Senior Scientists - CNS DiseasesDirectors of Clinical Research Senior Clinical Project Managers Benefits of attending: - Hear the latest in anti-depression drugs and how recent developments have affected current clinical trials
- Discover the newest in imaging analyses: monitoring and predictive capabilities
- Gain insight into patient recruitment for CNS Clinical Trials
- Evaluate the prediction of human efficacy in animal models
|
Events Home Page
